ANDAS 5 HOLDING
GenericsANDAS 5 HOLDING is a generic drug manufacturer focused on Neurology.
ANDAS 5 HOLDING's Key Drugs
ANDAS 5 HOLDING's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ANDAS 5 HOLDING's Recent FDA Approvals
New NDA/BLA approvals for ANDAS 5 HOLDING over the last two years — novel drugs only, excluding generics and label supplements.
ANDAS 5 HOLDING's Therapeutic Areas
ANDAS 5 HOLDING's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ANDAS 5 HOLDING's Top Competitors
ANDAS 5 HOLDING's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ANDAS 5 HOLDING Pipeline Snapshot
Active clinical trials for ANDAS 5 HOLDING across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1997-05-30
- Latest
- 2025-06-03
- Applications
- 4